Key points are not available for this paper at this time.
Rationale 95% CI, −0.21 to 1.62; P =0.1). Subgroup analysis demonstrated a significant benefit from febuxostat in patients without proteinuria ( P =0.005) and for whom serum creatinine concentration was lower than the median ( P =0.009). The incidence of gouty arthritis was significantly lower ( P =0.007) in the febuxostat group (0.91%) than in the placebo group (5.86%). Adverse events specific to febuxostat were not observed. Limitations GFR was estimated rather than measured, and patients with stages 4 and 5 CKD were excluded. Conclusions Compared to placebo, febuxostat did not mitigate the decline in kidney function among patients with stage 3 CKD and asymptomatic hyperuricemia. Funding Funded by Teijin Pharma Limited. Trial Registration Registered at the UMIN (University Hospital Medical Information Network) Clinical Trials Registry with study number UMIN000008343.
Kimura et al. (Fri,) studied this question.